To start delivering first doses in Europe in Q4 (Il Sole 24 Ore Radiocor) - Paris, 01 Jul - French specialty vaccine company Valneva said that the European Commission has granted marketing authorization in Europe for its single-dose vaccine, IXCHIQ, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

The decision marks the third approval the company has received for IXCHIQ following approval from the UX Food and Drug Administration in November 2023 and Health Canada last month. The company expects to deliver the first doses in Europe in the fourth quarter of 2024.

Chikungunya is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint pain, muscle pain, headache, nausea, fatigue and rash.

Joint pain is often debilitating and can persist for weeks to years.

AAA-Web

(RADIOCOR) 01-07-24 12:01:09 (0280) 5 NNNN